18 Oct Oral Semaglutide As Effective As Injectable In Reducing A1C and Weight Loss
MedicalResearch.com Interview with:
Melanie J Davies CBE MB ChB MD FRCP FRCGP
Professor of Diabetes Medicine
NIHR Senior Investigator Emeritus
Diabetes Research Centre
Leicester Diabetes Centre – Bloom
University of Leicester
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This was the first study to test the effectiveness of an oral GLP-1 in patients with type 2 diabetes.
The main findings were that compared to both placebo and a GLP-1, Semaglutide, delivered by sub-cutaneous injection weekly, the oral therapy delivered once a day produced better results than placebo and similar results to injectable GLP-1 with regard to reductions in HbA1c and weight loss.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: Readers should take away that this study provides good evidence that delivering GLP-1 therapy orally rather than by injectable therapy may be realized.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: At this stage two studies supported the company Novo Nordisk exploring further the potential for oral Semaglutide with a series of phase 3 studies which are now underway/
Disclosures: Professor Melanie Davies has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen, an advisory board member for Servier and as a speaker for Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceuticals International Inc.
She has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim and Janssen.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Davies M, Pieber TR, Hartoft-Nielsen M, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 DiabetesA Randomized Clinical Trial. JAMA. 2017;318(15):1460–1470. doi:10.1001/jama.2017.14752
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
Last Updated on October 18, 2017 by Marie Benz MD FAAD